Fabiflu 400mg tablet price in India, Used for COVID-19

The Fabiflu 400 mg tablet is an antiviral medication. It is used to treat adults with mild to moderate coronavirus disease (COVID-19). It works by preventing the virus from multiplying and therefore lowering the viral load in the body.

Fabiflu 400 mg tablets should not be self-medicated. Take it according to your doctor’s instructions for dosage and duration. Before using this medicine, contact your doctor if you have severe kidney or liver disease.

If you are pregnant, suspected to be pregnant, or breastfeeding, do not use it. It can have a negative impact on the development of the baby. Also, inform your doctor if you have a history of hypersensitivity to this drug, uric acid metabolism abnormalities, or gout.

The most common side effects of this medicine are increased uric acid levels in the blood, diarrhea, decreased white blood cell count (neutrophils), and increased liver enzymes. Consult with your doctor if any of these side effects bother you.

Benefits of Fabiflu 400 mg tablet

The COVID-19 pandemic has become the worst public-health crisis in a century. Fever, cough, loss of taste or smell, difficult breathing, nasal congestion, and diarrhoea are among the most common symptoms. A Fabiflu 400mg tablet is used to treat these symptoms in people who are only mildly infected and aid in the recovery process.

Fabiflu tablets should be taken only when prescribed by a doctor. If you feel that you have come into contact with someone who has been infected with COVID-19, or if you experience any of the symptoms listed above, contact your doctor immediately.

Fabiflu 400 dosage per day

Take Fabiflu 400 tablet only as per the dose and duration suggested by your doctor. Do not self-medicate. If you take too many Fabiflu 400 tablets, contact your doctor or go to the nearest hospital right away. If you have missed taking a dose of Fabiflu 400 tablet, dose and follow the normal dosing schedule. Do not take a double dose to compensate for the missing one.

References:

1. U Agrawal et al, Favipiravir: A new and emerging antiviral option in Covid 19, [Revised on 2020] [Accessed on 12th Apr 2021], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/pdf/main.pdf
2. Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: A. Drug Res, 2021, 71: 166–170 [Accessed on 12th Apr 2021], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043595/pdf/10-1055-a-1296-7935.pdf
3. Y Furuta, Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA Polymerase, Proc Jpn Acad Ser B Phys Biol Sci, 2017, 93(7):449-463 [Accessed on 12th Apr 2021], https://pubmed.ncbi.nlm.nih.gov/28769016/
4. Ciplamed, [Revised on 27th Nov 2020] [Accessed on 8th Jun 2021], https://ciplamed-library.com/content/ciplenza-tablets